CANC
Tema Oncology ETF
CANC is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations.
Global
EQUITY
Active
MANAGEMENT STYLE
86.2 M
ASSETS UNDER MGMT
75 bp
EXPENSES
Fund Basics
| Fund sponsor | Dawn Global Topco Ltd. |
| Category | Global |
| Asset class | Equity |
| Website | link... |
| Inception date | Aug 15, 2023 |
| Assets (mns) | $86 |
| Expense ratio | 75 bp |
| Currency | USD |
Sector Breakdown
Fund Structure
| Regulation | Open-Ended Fund |
| Distributions | Monthly |
| Taxation | 1099 |
| Stock selection | Proprietary |
| Weighting | Proprietary |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| REVOLUTION MEDICINES, INC. | 7.1 % |
| ELI LILLY & CO | 5.8 % |
| BRIDGEBIO PHARMA, INC. | 4.4 % |
| ROCHE HOLDINGS LTD-SPONS ADR | 4.1 % |
| ASTRAZENECA PLC | 4.0 % |
| NOVARTIS AG | 4.0 % |
| GENMAB A/S SPONSORED ADR | 3.9 % |
| ARCELLX, INC. | 3.7 % |
| NUVALENT, INC. CLASS A | 3.6 % |
| EXELIXIS INC | 3.1 % |
Constituent Breakdown
| Number of holdings | 52 |
| Herfindahl-Hirschman Index | 298 |
| Wgt avg mkt cap (mns) | $108,606 |
| Large cap (>$10bn) | 58.8% |
| Mid cap ($2-10bn) | 21.8% |
| Small cap (<$2bn) | 18.0% |
| Developed mkts. | 94.5% |
| Emerging mkts. | 4.5% |
Country Exposure
 |
UNITED STATES | 70.4 % |
 |
SWITZERLAND | 8.1 % |
 |
BRITAIN | 4.9 % |
 |
CHINA | 4.5 % |
 |
DENMARK | 3.9 % |
 |
NETHERLANDS | 3.4 % |
 |
JAPAN | 2.1 % |
 |
CANADA | 1.2 % |
 |
HONG KONG | 0.7 % |
Historical Performance
Standardized Performance (as of 10/31/2025)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 27.4% | 12.2% | 18.6% | -- | -- | -- | -- | 185.9% |
| Dividend Yield | 0.0% | 3.1% | 2.0% | -- | -- | -- | -- | 4.3% |
| Total Returns | 27.4% | 15.3% | 20.6% | -- | -- | -- | -- | 190.2% | Ann. Volatility | 26.8% | 26.2% | 23.4% | -- | -- | -- | -- | 480.5% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.02 | 37% |
| MSCI EAFE | 0.82 | 31% |
| MSCI Emg Mkts | 0.45 | 7% |
Liquidity Measures
| Avg. volume (000) | 9 |
| ADV traded (mns) | $0 |
| Turnover | 0.3% |
| Avg. Bid/Ask (% of price) | 0.50% |
Technical Indicators
| Recent close | $30.68 |
| 30d moving avg. | $30.03 |
| Annualized volatility | 20.1% |
| Relative strength (RSI) | 61 |
| Short interest | 0.2% |
Distributions
Assets Under Management (mns)
Money Flows (mns)
Short Interest (as % of shares outstanding)
Long Money Flows (mns)
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. |
Expenses vs. |
ALTAR Score™ vs. |
|---|---|---|---|---|
| HRTS | Tema Heart & Health ETF | 34.9% | 0 bp | +2.3% |
| IDNA | iShares Genomics Immunology and Healthcare ETF | 26.1% | -28 bp | -2.3% |
| IXJ | iShares Global Healthcare ETF | 25.7% | -33 bp | +7.0% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 21.9% | -15 bp | +8.8% |
| XBI | State Street SPDR S&P Biotech ETF | 21.8% | -40 bp | -2.2% |
| BBC | Virtus LifeSci Biotech Clinical Trials ETF | 20.9% | +4 bp | 0.0% |
| WDNA | WisdomTree BioRevolution Fund | 20.8% | -30 bp | -2.3% |
| AGNG | Global X Aging Population ETF | 20.2% | -25 bp | +4.8% |
| VHT | Vanguard Health Care ETF | 19.9% | -66 bp | +5.8% |
| IYH | iShares U.S. Healthcare ETF | 19.5% | -35 bp | +6.6% |
Risk and Returns: CANC vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Book value per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2024 | 2025 | 2026 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 11/10/2025
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
AVOID
Not worthwhile for most investors. A rating of AVOID is assigned to ETFs with ALTAR Scores in the lowest quintile (the bottom 20%) of their category. Often, funds in this category consist of stocks with little if any history or expectation of profitability, and as a result our fundamentally-driven analysis may be less relevant.
ALTAR Score™
CANC
-2.7%
Cat. Avg
4.3%
ALTAR Score™ Calculation
Category Overview
There are 371 funds in the Global Equity category, with an average ALTAR Score™
of 4.3% and a standard deviation of
3.2%. CANC's ALTAR Score™ is approximately
2.2 standard deviations
below
the category average. This places CANC in the 1st percentile among funds in the category.
Sell Side Consensus Rating
Sell-side recommendations on the ETF's individual constituents
CANCSELL
U/W
HOLD
O/W
BUY